Sermorelin has an unusual regulatory story worth understanding on its own terms: the prescription drug Geref was FDA-approved, and it left the market for business reasons, not because it failed a trial or raised a safety flag.
What sermorelin is
Sermorelin is a growth hormone-releasing hormone (GHRH) analog, a shorter-acting relative of compounds like CJC-1295. It was marketed under the brand name Geref.
What's actually been studied
- Original FDA approval. The FDA approved sermorelin (Geref) for two pediatric indications: diagnostic testing for growth hormone deficiency in children, and treatment of idiopathic growth hormone deficiency causing growth failure in children.
- Discontinuation. The manufacturer, EMD Serono, voluntarily withdrew Geref from the US market in 2008. Available reporting attributes this to commercial reasons, a shrinking market for pediatric GH-deficiency diagnostics as synthetic growth hormone came to dominate treatment, rather than a safety or efficacy finding.
Where the evidence is thin
The trials supporting sermorelin's original approval were conducted in children with a specific diagnosed condition (growth hormone deficiency), decades ago, for a diagnostic and treatment purpose distinct from how it's discussed in adult research-peptide circles today. I was not able to locate a comparably rigorous, modern trial base establishing outcomes in healthy adults using sermorelin for the purposes it's typically sold for now.
The regulatory picture
The FDA currently lists sermorelin (Geref) as a discontinued drug product. Because the FDA does not oversee compounded drugs, sermorelin remains available through compounding pharmacies by prescription, but it holds no current, active approval for any indication. The research-chemical version sold by peptide vendors is a separate product from either the discontinued brand-name drug or a pharmacy-compounded version. It's sold by research chemical vendors strictly for laboratory research, not for human use.
Papa's take
I think sermorelin's history gets flattened online into either "it was banned" (not accurate, it was a business decision) or "it's FDA-approved" (also not accurate, not currently). The honest version is in between: it was approved for a narrow pediatric use, that approval was voluntarily dropped for commercial reasons, and the modern adult use case doesn't have the same trial record the original pediatric approval was built on.
Sourcing for research
If you're sourcing sermorelin for laboratory research, purity documentation matters. See my vendor comparisons for how I evaluate third-party certificates of analysis.